Literature DB >> 7906671

A novel case of compound heterozygosity with "Normandy"/type I von Willebrand disease (vWD). Direct demonstration of the segregation of one allele with a defective expression at the mRNA level causing type I vWD.

V Siguret1, J M Lavergne, G Chérel, C Boyer-Neumann, A S Ribba, B R Bahnak, D Meyer, G Piétu.   

Abstract

We report the case of a family with type I von Willebrand disease (vWD), characterized by a quantitative defect in von Willebrand factor (vWF), associated with a defective binding of vWF to factor VIII (FVIII) also called the "Normandy" variant of vWD. PCR products from genomic DNA of the family members were analysed in the region coding for the binding domain of vWF to FVIII. It showed that the proposita and one of her sons were heterozygous for the Arg91Gln missense mutation, abolishing an MspI restriction enzyme site located in exon 20. The transcription of the normal and mutated alleles was tested by the amplification of cDNA after reverse transcription of platelet mRNA in this region. A total lack of expression of the normal allele was observed in the proposita, who appeared as a compound heterozygous with one allele mutated at Arg91 and a "silent" expression of the other one. The segregation of the "silent" allele was studied in the family with the exonic BstEII RFLP both at the DNA and mRNA levels. The proposita has transmitted her "silent" allele to her daughter and to another son. As this son was informative for this RFLP, the absence of expression of the allele could be demonstrated at the mRNA level, providing evidence that this defect was responsible for his type I vWD.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7906671     DOI: 10.1007/bf00210590

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  27 in total

1.  A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction.

Authors:  C Mazurier; J Dieval; S Jorieux; J Delobel; M Goudemand
Journal:  Blood       Date:  1990-01-01       Impact factor: 22.113

2.  Nucleotide sequence of pre-pro-von Willebrand factor cDNA.

Authors:  D Bonthron; E C Orr; L M Mitsock; D Ginsburg; R I Handin; S H Orkin
Journal:  Nucleic Acids Res       Date:  1986-09-11       Impact factor: 16.971

3.  Evidence for a von Willebrand factor defect in factor VIII binding in three members of a family previously misdiagnosed mild haemophilia A and haemophilia A carriers: consequences for therapy and genetic counselling.

Authors:  C Mazurier; C Gaucher; S Jorieux; A Parquet-Gernez; M Goudemand
Journal:  Br J Haematol       Date:  1990-11       Impact factor: 6.998

Review 4.  von Willebrand disease: a database of point mutations, insertions, and deletions. For the Consortium on von Willebrand Factor Mutations and Polymorphisms, and the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.

Authors:  D Ginsburg; J E Sadler
Journal:  Thromb Haemost       Date:  1993-02-01       Impact factor: 5.249

Review 5.  A database of polymorphisms in the von Willebrand factor gene and pseudogene. For the Consortium on von Willebrand Factor Mutations and Polymorphisms and the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.

Authors:  J E Sadler; D Ginsburg
Journal:  Thromb Haemost       Date:  1993-02-01       Impact factor: 5.249

6.  The mutation Arg (53)----Trp causes von Willebrand disease Normandy by abolishing binding to factor VIII. Studies with recombinant von Willebrand factor.

Authors:  S Jorieux; E A Tuley; C Gaucher; C Mazurier; J E Sadler
Journal:  Blood       Date:  1992-02-01       Impact factor: 22.113

7.  Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease.

Authors:  P A Kroner; K D Friedman; S A Fahs; J P Scott; R R Montgomery
Journal:  J Biol Chem       Date:  1991-10-15       Impact factor: 5.157

8.  Duplication of a methionine within the glycoprotein Ib binding domain of von Willebrand factor detected by denaturing gradient gel electrophoresis in a patient with type IIB von Willebrand disease.

Authors:  A S Ribba; J M Lavergne; B R Bahnak; A Derlon; G Piétu; D Meyer
Journal:  Blood       Date:  1991-10-01       Impact factor: 22.113

9.  Epidemiological investigation of the prevalence of von Willebrand's disease.

Authors:  F Rodeghiero; G Castaman; E Dini
Journal:  Blood       Date:  1987-02       Impact factor: 22.113

10.  Mutations in severe, type III von Willebrand's disease in the Dutch population: candidate missense and nonsense mutations associated with reduced levels of von Willebrand factor messenger RNA.

Authors:  J C Eikenboom; H K Ploos van Amstel; P H Reitsma; E Briët
Journal:  Thromb Haemost       Date:  1992-10-05       Impact factor: 5.249

View more
  1 in total

1.  Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D'D3 and D4 domains.

Authors:  Monica Sacco; Stefano Lancellotti; Mattia Ferrarese; Francesco Bernardi; Mirko Pinotti; Maira Tardugno; Erica De Candia; Leonardo Di Gennaro; Maria Basso; Betti Giusti; Massimiliano Papi; Giordano Perini; Giancarlo Castaman; Raimondo De Cristofaro
Journal:  Blood Adv       Date:  2020-07-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.